Rogel Cancer Center: University of Michigan

First-in-Human Trial Tests Herpes Virus-Based Gene Therapy for Neurogenic Bladder in Spinal Cord Injury Patients

2 months ago

• A phase 1b/2a clinical trial has begun testing EG110A, a modified herpes virus vector that delivers botulinum toxin genes to treat neurogenic bladder in spinal cord injury patients. • Unlike current treatments requiring multiple bladder injections every six months, this innovative gene therapy could potentially provide relief from urinary incontinence for several years with a single procedure. • The 52-week trial is recruiting patients across four U.S. centers, with participants receiving intradetrusor injections at varying dose levels to determine safety, tolerability, and initial efficacy.

Landmark Breast Cancer Trials Reshape Treatment Paradigms for HR-positive, HER2-negative Disease

7 months ago

• KEYNOTE-756 explores chemoimmunotherapy's role in high-risk HR-positive, HER2-negative breast cancer, showing improved pathologic complete response rates, but event-free survival data is pending. • The FDA approved adjuvant ribociclib based on the NATALEE trial, broadening CDK4/6 inhibitor eligibility to include lower-risk patients with HR-positive, HER2-negative breast cancer. • MonarchE trial data supports adjuvant abemaciclib for high-risk patients, demonstrating a 6% absolute difference in invasive disease-free survival, but diarrhea management is crucial. • Treatment decisions now involve navigating side effect profiles, therapy duration, and individual risk factors when choosing between abemaciclib and ribociclib for eligible patients.

Kineta's KVA12123 Clinical Data to be Presented at SITC 2024

8 months ago

• Kineta's KVA12123, a VISTA-blocking immunotherapy, will be featured in a poster presentation at the SITC 2024 Annual Meeting, highlighting new clinical data. • The presentation will cover an ongoing Phase 1/2 clinical trial of KVA12123 alone and in combination with pembrolizumab in advanced solid tumors. • The poster, presented by Dr. Jason Henry from Sarah Cannon Research Institute, will offer insights into the drug's efficacy and safety profiles. • KVA12123 represents a novel approach to address immune suppression within the tumor microenvironment, potentially effective across multiple cancer types.